Skip to main content
Fig. 4 | BMC Pharmacology and Toxicology

Fig. 4

From: Spontaneous recovery from sunitinib-induced disruption of sarcomere in human iPSC-cardiomyocytes and possible involvement of the Hippo pathway

Fig. 4

Mitigation of sunitinib-induced sarcomere disruption via the inhibition of MST1/2 using XMU-MP-1 (A) Representative immunostaining results for iPSC-CMs following exposure to DMSO or sunitinib with or without XMU-MP-1 for 72 h. The leftmost, middle, and rightmost images represent the DMSO, 1 μM sunitinib, and sunitinib/XMU-MP-1 co-treated groups, respectively (60×; scale bar: 50 μm). (B) Quantitative analysis of sarcomere morphology via high-content image analysis. Data represent the percent change in the HSI of iPSC-CMs relative to the control and are expressed as the mean ratios ± SD. Approximately 200 cells were analyzed in each well, one well was used for each data point, and five wells were used as the data for one group (n = 5 wells/group). #: p < 0.025, ##: p < 0.005 versus control groups using Shirley-Williams’ multiple comparison test. *: p < 0.025 versus 1 μM sunitinib group using Williams’ multiple comparison test

Back to article page